Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
AB Concentrated International Growth C CICGX
- NAV / 1-Day Return 9.84 / −1.11 %
- Total Assets 185.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.900%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Foreign Large Growth
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 33%
USD | NAV as of Apr 25, 2024 | 1-Day Return as of Apr 25, 2024, 10:10 PM GMT+0
Morningstar’s Analysis CICGX
Will CICGX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Novo Nordisk A/S Class B | 6.62 | 14.4 Mil | Healthcare |
ASML Holding NV | 6.31 | 13.7 Mil | Technology |
SAP SE | 5.63 | 12.2 Mil | Technology |
Compass Group PLC | 4.50 | 9.8 Mil | Consumer Cyclical |
Keyence Corp | 4.03 | 8.7 Mil | Technology |
Pan Pacific International Holdings Corp | 3.88 | 8.4 Mil | Consumer Defensive |
Terumo Corp | 3.83 | 8.3 Mil | Healthcare |
Cellnex Telecom SA | 3.44 | 7.5 Mil | Real Estate |
Sika AG | 3.16 | 6.9 Mil | Basic Materials |
Lonza Group Ltd | 3.15 | 6.8 Mil | Healthcare |